News | 15 December 2021
Pfizer’s Covid-19 drug 90 % effective
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
During H1 FY2022, the revenues and operating profit margin (OPM) for ICRA sample set showed sharp improvement aided by volume uptick in Covid-19 and allied tests and also demand traction for non-Covid tests
It accelerates the company’s vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
FDA changes inspection classification of the facility to Voluntary Action Indicated
The campaign “Care is Just An Aster Away” was launched along with the unveiling of the new corporate logo on Burj Khalifa on 11th December
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
The total cost of the project is estimated at Rs 30 crore
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
The Uteshiya facility, licensed by Healthium, will exclusively manufacture Healthium’s arthroscopy portfolio, including patented products in India and U.S.
Organised by the Indian Stroke Association, it has attracted over 800 doctors from India and overseas
This is the fourth facility from the company to receive this registration
.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Sputnik M is a new member of the Sputnik vaccines family
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
Subscribe To Our Newsletter & Stay Updated
